U.S. Patient and Trademark Office, U.S. DEPARTMENT OF C.

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS con-

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number			10798144		
Filing Date			2004-03-10		
	First Named Inventor Young		Hoon PARK		
	Art Unit		1762		
	Examiner Name	LIN, J	AMES		
Attorney Docket Number		er	VPL-0085		

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number			Name of Pate of cited Docu	entee or Applicant ment	s,Columns,Lines where ant Passages or Relevant as Appear			
	1									
If you wis	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	JCATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Publication Number Kind Code1 Publication Name of Patentee or Applicant of cited Document		Releva	Columns,Lines whe int Passages or Rele s Appear	re vant			
	1									
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add	
				FOREIG	SN PA1	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or v	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	T4
	1	11-162856	JP			1999-06-18		v	with English Abstract	
	2	2001-073146	JP			2001-03-21		v	with English Abstract	
	3	11-269652	JP			1999-10-05		v	with English Abstract	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10798144		
Filing Date		2004-03-10		
First Named Inventor Young		Hoon PARK		
Art Unit		1762		
Examiner Name LIN, J		AMES		
Attorney Docket Number		VPI_0085		

Date Considered

with English Abstract

								-		
	5	07-273092	JP		1995-10-20		with English Abstract			
	6	2002-134490	JP		2002-05-10		with English Abstract			
	7	03/009352	wo		2003-01-30		PCT			
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
			NON-PATEN	IT LITE	RATURE DO	CUMENTS	Remove			
Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposishum, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5		
1										
If you wish to add additional non-patent literature document citation information please click the Add button Add										

1002 11 27

1 See Kind Codes of USPTO Patient Documents at sense USPTO.GDV or MREP 981.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patient documents, the endeation of the year of the insign of the Emperor must precede the seniar number of the patient document.

EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sandard ST.3. ³ For Japanese patent documents, the indication of the year of the regar of the Emperor most precede the serial number of the patent document. "A found of counses" by the perportain expended as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark then if English language translation is attached.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10798144
Filing Date		2004-03-10
First Named Inventor	Young	Hoon PARK
Art Unit		1762
Examiner Name LIN, J		AMES
Attorney Docket Number		YPL-0085

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
X	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

OR

That no item of information contained in the information disclosure statement was cited in a communication from a
foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	of the agreement.								
	Signature	/James J. Merrick/	Date (YYYY-MM-DD)	2007-01-17					
	Name/Print	James J Merrick	Registration Number	43801					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2231-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.